

DEPARTMENT OF ENERGY

Federal Energy Regulatory
Commission

18 CFR Part 157

[Docket No. RM98–9–000, Order No. 603]

Revision of Existing Regulations
Under Part 157 and Related Sections of
the Commission's Regulations Under
the Natural Gas Act; Correction

Issued March 13, 2001.

AGENCY: Federal Energy Regulatory
Commission, DOE.

ACTION: Technical amendment.

SUMMARY: In Order No. 603 published in the **Federal Register** on May 14, 1999 (64 FR 26571) the Federal Energy Regulation Commission inadvertently removed a paragraph of the Commission's regulations that required that a company report changes in rate schedules authorized under the Commission's regulations. This technical notice corrects the previous error by amending the regulations to add the removed paragraph.

DATES: Effective March 19, 2001.**FOR FURTHER INFORMATION CONTACT:**

Michael J. McGehee, Office of Pipeline Regulation, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, (202) 208–2257.

Carolyn Van Der Jagt, Office of the General Counsel, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, (202) 208–2246.

SUPPLEMENTARY INFORMATION:**List of Subjects in 18 CFR Part 157**

Administrative practice and procedure, Natural gas, Reporting and record keeping requirements.

In consideration of the foregoing, the Commission amends Part 157, Chapter I, Title 18, *Code of Federal Regulations*, as follows.

**PART 157—APPLICATIONS FOR
CERTIFICATES OF PUBLIC
CONVENIENCE AND NECESSITY AND
FOR ORDERS PERMITTING AND
APPROVING ABANDONMENT UNDER
SECTION 7 OF THE NATURAL GAS
ACT**

1. The authority for Part 157 continues to read as follows:

Authority: 15 U.S.C. 717–717w, 3301–3432; 42 U.S.C. 7101–7352.

2. In § 157.207, paragraphs (f) and (g) are redesignated as (g) and (h), respectively, and a new paragraph (f) is added to read as follows:

§ 157.207 General reporting requirements.

* * * * *

(f) For each change in rate schedule authorized under § 157.217, the information specified in § 157.217(b);

* * * * *

David P. Boergers,
Secretary.

[FR Doc. 01–6654 Filed 3–16–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICESSubstance Abuse and Mental Health
Services Administration

21 CFR Part 291

42 CFR Part 8

RIN 0910–AA52

**Opioid Drugs in Maintenance and
Detoxification Treatment of Opiate
Addiction; Repeal of Current
Regulations and Issuance of New
Regulations: Delay of Effective Date
and Resultant Amendments to the
Final Rule**

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services.

ACTION: Final rule; delay of effective date and resultant amendments to the final rule.

SUMMARY: In accordance with the memorandum of January 20, 2001, from the Assistant to the President and Chief of Staff, entitled “Regulatory Review Plan,” published in the **Federal Register** on January 24, 2001, this action temporarily delays for 60 days the effective date of the rule entitled “Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Repeal of Current Regulations and Issuance of New Regulations” published in the **Federal Register** on January 17, 2001 (66 FR 4076). It also amends the final rule published on January 17 to extend by 60 days the dates outlines in the rule for transitional certification of opioid treatment programs so as to be consistent with extending the effective date by that amount of time. That rule repealed the existing narcotic treatment regulations enforced by the Food and Drug Administration (FDA), and created a new regulatory system based on an accreditation model. It also shifted administrative responsibility and oversight of the program from FDA to SAMHSA.

DATES: This rule is effective March 18, 2001. The effective date of the “Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction” published in the **Federal Register** on January 17, 2001 (66 FR 4076), is delayed for 60 days, from March 19, 2001 to a new effective date of May 18, 2001.

FOR FURTHER INFORMATION CONTACT:

Nicholas Reuter, Center for Substance Abuse Treatment (CSAT), SAMHSA, Rockwell II, 5600 Fishers Lane, Rm 12–05, Rockville, MD 20857, 301–443–0457, email: nreuter@samsha.gov.

SUPPLEMENTARY INFORMATION: To the extent that 5 U.S.C. section 553 applies to this action, it is exempt from notice and comment because it constitutes a rule of procedure under 5 U.S.C. section 553(b)(A). Alternatively, the Department's implementation of this rule without opportunity for public comment, effective immediately upon publication today in the **Federal Register**, is based on the good cause exceptions in 5 U.S.C. section 553(b)(B) and 553(b)(3). Seeking public comment is impracticable, unnecessary and contrary to the public interest. The temporary 60-day delay in effective date is necessary to give Department officials the opportunity for further review and consideration of new regulations, consistent with the Assistant to the President's memorandum of January 20, 2001. Given the imminence of the effective date, seeking prior public comment on this temporary delay would have been impractical, as well as contrary to the public interest in the orderly promulgation and implementation of regulations.

List of Subjects in 42 CFR Part 8

Health professions, Levo-Alpha-Acetyl-Methadol (LAAM), Methadone, Reporting and recordkeeping requirements.

Dated: January 14, 2001.

Tommy G. Thompson,*Department of Health and Human Services.*

For the reasons set forth above, Part 8 of Title 42 of the Code of Federal Regulations is amended as follows:

1. The authority citation for Part 8 continue to read as follows:

21 U.S.C. 823; Sections 301(d), 543, and 1976 of the 42 U.S.C. 257a, 290aa(d), 290 dd–2, 300x–23, 300x–27(a), 300y–11.

2. Section 8.11(d) is revised to read as follows:

**§ 8.11 Opioid treatment program
certification.**

* * * * *

(d) *Transitional certification.* OTPs that before May 18, 2001 were the subject of a current, valid approval by FDA under 21 CFR, part 291 (contained in the 21 CFR parts 200 to 299 edition, revised as of July 1, 2000), are deemed to be the subject of a current valid certification for purposes of paragraph (a)(11) of this section. Such "transitional certification" will expire on August 17, 2001 unless the OTP submits the information required by paragraph (b) of this section to SAMHSA on or before August 17, 2001. In addition to this application, OTPs must certify with a written statement signed by the program sponsor, that they will apply for accreditation within 90 days of the date SAMHSA approves the second accreditation body. Transitional certification, in that case, will expire on May 19, 2003. SAMHSA may extend the transitional certification of an OTP for up to one additional year provided the OTP demonstrates that it has applied for accreditation, that an accreditation survey has taken place or is scheduled to take place, and that an accreditation decision is expected within a reasonable period of time (e.g., within 90 days from the date of survey). Transitional certification under this section may be suspended or revoked in accordance with § 8.14.

* * * *

[FR Doc. 01-6745 Filed 3-16-01; 8:45 am]

BILLING CODE 4160-20-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, and 522

New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for two approved new animal drug applications (NADA's) from Wendt Laboratories, Inc., to First Priority, Inc.

DATES: This rule is effective March 19, 2001.

FOR FURTHER INFORMATION CONTACT: Norman J. Turner, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0214.

SUPPLEMENTARY INFORMATION: Wendt Laboratories, Inc., 100 Nancy Dr., Belle Plaine, MN 56011, has informed FDA that it has transferred to First Priority, Inc., 1585 Todd Farm Dr., Elgin, IL 60123, ownership of, and all rights and interests in NADA 48-646 for Therazone Injection and NADA 48-647 for Therazone Tablets. Accordingly, the agency is amending the regulations in 21 CFR 520.1720a and 522.1720 to reflect the transfer of ownership.

In addition, First Priority, Inc., has not been previously listed in the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for the firm.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A), because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520 and 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, and 522 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding an entry for "First Priority, Inc." and in the table in paragraph (c)(2) by numerically adding an entry for "058829" to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address					Drug labeler code	
* * * *						
First Priority, Inc.,	1585 Todd Farm Dr.,	Elgin, IL	60123		058829	
* * * *						
(2) * * *						
Drug labeler code					Firm name and address	
* * * *						
058829					First Priority, Inc., 1585 Todd Farm Dr., Elgin, IL 60123.	
* * * *						